Skip to main content
SpringerLink
Log in

Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials

  • Comment
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

Certain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Richardson, P. G. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl. J. Med. 387, 132–147 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sonneveld, P. et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 390, 301–313 (2024).

    Article  CAS  PubMed  Google Scholar 

  3. McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J. Clin. Oncol. 35, 3279–3289 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Moreau, P. et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1378–1390 (2021).

    Article  CAS  PubMed  Google Scholar 

  5. Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988–5999 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Mateos, M.-V. et al. GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab (D), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. Blood 142 (suppl. 1), 209 (2023).

    Article  Google Scholar 

  7. Rajkumar, S. V., Kumar, S., Lonial, S. & Mateos, M. V. Smoldering multiple myeloma current treatment algorithms. Blood Cancer J. 12, 129 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lonial, S. et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J. Clin. Oncol. 38, 1126–1137 (2020).

    Article  CAS  PubMed  Google Scholar 

  9. Mateos, M. V. et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).

    Article  CAS  PubMed  Google Scholar 

  10. Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538–e548 (2014).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology and Hematologic Malignancies, Department of Medicine, University of Utah, Salt Lake City, UT, USA

    Ghulam Rehman Mohyuddin

  2. Division of Blood and Marrow Transplantation, Department of Medicine, University of California San Diego, San Diego, CA, USA

    Aaron M. Goodman

Authors
  1. Ghulam Rehman Mohyuddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aaron M. Goodman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ghulam Rehman Mohyuddin.

Ethics declarations

Competing interests

G.R.M. has received royalties from MashupMD for writing, and his institution has received research funding from Janssen as part of his role as a site principal investigator of a clinical trial. A.M.G. has acted as a consultant of Seattle Genetics.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohyuddin, G.R., Goodman, A.M. Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00895-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41571-024-00895-x

  • Springer Nature Limited

Search

Navigation